At a glance
| Structure | Amidated GHRH(1–29) |
|---|---|
| Historical US brand | Geref |
| Historical uses | Pediatric GH deficiency and GH-reserve testing |
| US market history | Geref discontinued; approvals withdrawn in 2009 |
| FDA finding | Not withdrawn for safety or effectiveness reasons |
Overview
Sermorelin reproduces the biologically active first 29 amino acids of growth hormone-releasing hormone with an amidated terminus. Its historical pharmaceutical uses included testing pituitary GH reserve and treating selected children with growth failure caused by GH deficiency. Geref was discontinued, and FDA later determined that removal from sale was not for safety or effectiveness reasons. That history is more precise than describing all sermorelin as either never approved or currently approved for wellness. Contemporary compounded preparations have their own quality and evidence questions. Trials of tesamorelin, a different GHRH analog used in HIV-associated lipodystrophy, cannot substitute for sermorelin-specific outcome evidence.
How it works
Sermorelin binds GHRH receptors on pituitary somatotroph cells and stimulates endogenous GH release. The response requires functioning pituitary tissue and is shaped by somatostatin and normal endocrine feedback. GH can then increase hepatic and tissue IGF-1 production. This differs from injecting GH directly, but preservation of feedback does not by itself establish clinical superiority or exclude adverse effects from altering the GH–IGF-1 axis.
The pediatric evidence
A multicenter open-label study enrolled 110 previously untreated prepubertal children with GH deficiency. Growth velocity increased during treatment, with 86 children included in the efficacy analysis. The design and selected population matter: this was not a placebo-controlled longevity trial or evidence that healthy adults benefit from raising GH.
Supporting sources [1]
Why the approval history needs qualification
FDA records identify distinct diagnostic and pediatric Geref approvals. The manufacturer discontinued both presentations, and approvals were withdrawn in 2009. FDA’s 2013 determination found that their removal from sale was not for safety or effectiveness reasons. This does not create an approved indication for contemporary compounded weight-loss or anti-aging regimens.
Supporting sources [2]
What remains uncertain in wellness use
The pediatric study reported generally favorable tolerability, but its size, duration, and patient selection cannot define long-term risk in healthy older adults. An endocrine response should be interpreted alongside glucose metabolism, symptoms, and the reason GH testing was undertaken. Compounded product composition and sterility are additional questions beyond the molecule’s historical evidence.
Are tesamorelin results evidence for sermorelin?
No. Both stimulate the GHRH receptor, but they differ in structure, exposure, approved use, and trial populations. Reduced visceral fat in a tesamorelin trial cannot be relabeled as a sermorelin result. Clinical claims should cite the actual molecule, formulation, population, and outcome studied.
Supporting sources [3]
Reading this profile
Jurisdiction: United States: historical Geref approvals were withdrawn after discontinuation; compounded sermorelin products are not FDA approved.. Molecular class: Synthetic amidated 29-amino-acid GHRH fragment.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Geref International Study Group: pediatric GHRH(1–29) trial ↗Original research · Checked 2026-10-27
- FDA determination on discontinued Geref products ↗Regulatory source · Checked 2026-10-27
- FDA clinical review of tesamorelin and prior GHRH products ↗Regulatory source · Checked 2026-10-27